Cited 2 times in
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정준 | - |
dc.date.accessioned | 2021-01-19T08:03:24Z | - |
dc.date.available | 2021-01-19T08:03:24Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0960-9776 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/181441 | - |
dc.description.abstract | Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | BREAST | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Min Ho Park | - |
dc.contributor.googleauthor | Soo Jung Lee | - |
dc.contributor.googleauthor | Woo Chul Noh | - |
dc.contributor.googleauthor | Chang Wan Jeon | - |
dc.contributor.googleauthor | Seok Won Lee | - |
dc.contributor.googleauthor | Gil Soo Son | - |
dc.contributor.googleauthor | Byung-In Moon | - |
dc.contributor.googleauthor | Jin Sun Lee | - |
dc.contributor.googleauthor | Sung Soo Kang | - |
dc.contributor.googleauthor | Young Jin Suh | - |
dc.contributor.googleauthor | Geumhee Gwak | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Young Bum Yoo | - |
dc.contributor.googleauthor | Hyun-Ah Kim | - |
dc.contributor.googleauthor | Min Young Kim | - |
dc.contributor.googleauthor | Ju Yeon Kim | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.identifier.doi | 10.1016/j.breast.2020.09.004 | - |
dc.contributor.localId | A03727 | - |
dc.relation.journalcode | J00400 | - |
dc.identifier.eissn | 1532-3080 | - |
dc.identifier.pmid | 32980648 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Eribulin mesylate | - |
dc.subject.keyword | Korean patients | - |
dc.subject.keyword | Retrospective study | - |
dc.contributor.alternativeName | Jeong, Joon | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.citation.volume | 54 | - |
dc.citation.startPage | 121 | - |
dc.citation.endPage | 126 | - |
dc.identifier.bibliographicCitation | BREAST, Vol.54 : 121-126, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.